Last updated: August 17, 2026
COMBOGESIC is a fixed-dose analgesic combination of acetaminophen, also called paracetamol, and ibuprofen. Its commercial value depends less on novel active ingredients than on formulation performance, dosing convenience, tolerability, regulatory positioning, and hospital procurement economics. The strongest excipient opportunities are route-specific: sterile aqueous excipients for intravenous COMBOGESIC and solid-dose excipients that support rapid disintegration, content uniformity, and gastrointestinal tolerability for oral products.
What is COMBOGESIC and which formulations are commercially relevant?
COMBOGESIC products combine acetaminophen and ibuprofen in fixed ratios. The best-known presentations include oral tablets and an intravenous formulation containing acetaminophen 1,000 mg and ibuprofen 300 mg per 100 mL, subject to jurisdiction-specific labeling. AFT Pharmaceuticals developed and commercialized the product portfolio, with market access varying by country and formulation.[1][2]
| Product attribute |
Oral COMBOGESIC |
Intravenous COMBOGESIC |
| Active ingredients |
Acetaminophen and ibuprofen |
Acetaminophen and ibuprofen |
| Primary use |
Short-term mild-to-moderate pain and fever |
Short-term acute pain and fever when IV administration is appropriate |
| Principal formulation issue |
Dissolution, tablet size, taste, gastrointestinal tolerability |
Solubility, pH, precipitation, oxidation, sterility, container compatibility |
| Main commercial channel |
Retail pharmacy, e-commerce, hospitals |
Hospitals, ambulatory surgery, inpatient care |
| Main competitive set |
Separate acetaminophen and ibuprofen products; other fixed-dose analgesics |
IV acetaminophen, injectable NSAIDs, opioids, multimodal analgesia protocols |
| Main regulatory risk |
Combination-drug requirements and label compliance |
Sterile manufacturing, infusion compatibility, renal and hepatic safety labeling |
The combination is commercially differentiated by simultaneous analgesic mechanisms and reduced pill burden. The value proposition is strongest where clinicians seek opioid-sparing multimodal analgesia or where patients would otherwise take two separate medicines.
What excipients are used in COMBOGESIC?
Public product information identifies excipients at the product and jurisdiction level, but the full quantitative formulation and process parameters are generally not disclosed in commercial labels. The excipient strategy can therefore be evaluated by function rather than by assuming a complete quantitative recipe.
Oral tablet excipient strategy
An oral COMBOGESIC tablet must accommodate two chemically distinct active ingredients with different solubility, compressibility, and dose characteristics. The formulation generally requires:
- A diluent or filler to achieve tablet mass and improve manufacturability.
- A binder to maintain mechanical strength.
- A disintegrant to support rapid breakup after administration.
- A lubricant and glidant to control ejection and powder flow.
- A film-coating system to improve swallowability, appearance, moisture protection, and product identification.
- Potential pH-modifying or buffering components to manage dissolution behavior.
- Packaging protection against moisture and temperature stress.
The most valuable excipient work is not simple substitution. It is the development of a robust formulation that delivers rapid release for both actives without creating segregation, sticking, capping, excessive tablet size, or delayed ibuprofen dissolution.
Ibuprofen has poor aqueous solubility. Acetaminophen is more soluble but can present high-dose tablet-mass challenges. A formulation that improves ibuprofen wetting or dissolution while preserving acetaminophen release can create a meaningful quality and differentiation advantage.
Potential technologies include:
-
Superdisintegrant systems. Crospovidone, croscarmellose sodium, and sodium starch glycolate can be screened for rapid tablet breakup. The selection must account for compression force, tablet hardness, and storage-related disintegration drift.
-
Wetting and dissolution aids. Surfactants or amphiphilic excipients may improve ibuprofen dispersion. Regulatory acceptability, taste, stability, and gastrointestinal tolerability constrain the choice.
-
Co-processing. Co-processed excipients can improve powder flow and direct compression performance, reducing manufacturing complexity. This is useful for high-throughput generic or private-label manufacturing.
-
Taste and swallowability systems. Film coatings, smooth tablet surfaces, and smaller unit doses can improve patient acceptance. Taste masking becomes more important for chewable, dispersible, or pediatric formats.
-
Modified-release protection. A sustained-release version would require a separate clinical and regulatory strategy. It cannot be assumed to be interchangeable with an immediate-release COMBOGESIC product.
Intravenous excipient strategy
The IV product presents the stronger technical barrier. Acetaminophen and ibuprofen must remain physically and chemically stable in an aqueous sterile solution throughout manufacturing, storage, transport, and administration.
The formulation must control:
- Solubility and precipitation.
- Solution pH.
- Osmolality.
- Particulate formation.
- Oxidation and degradation.
- Container closure interaction.
- Light sensitivity.
- Infusion-line compatibility.
- Sterilization or aseptic-processing requirements.
Possible excipient functions include buffering, pH adjustment, tonicity control, solubilization, chelation, and oxidation control. The permissible excipient set is narrower than for oral tablets because intravenous administration increases the safety burden. Every excipient must be evaluated for parenteral suitability, impurity profile, toxicological history, and compatibility with the intended infusion container.
A commercially useful IV excipient platform could improve one or more of the following:
- Higher active concentration in a smaller infusion volume.
- Longer in-use stability after vial or bag activation.
- Reduced precipitation risk during dilution.
- Compatibility with common hospital infusion materials.
- Lower particulate burden.
- More efficient terminal sterilization or aseptic processing.
- Longer shelf life at standard room-temperature storage.
These attributes can support hospital formulary adoption even when the active ingredients are established.
What excipient patents could protect COMBOGESIC-type products?
Excipient claims are most defensible when they are tied to a demonstrated technical effect. A broad claim covering acetaminophen, ibuprofen, and ordinary pharmaceutical excipients would face substantial validity and obviousness risk.
Potential claim categories include:
| Claim category |
Commercial relevance |
Patent strength |
| Specific acetaminophen-to-ibuprofen ratio |
Protects the fixed-dose product |
Moderate, depending on prior art and clinical evidence |
| Defined pH range and buffer system |
Important for IV stability |
Moderate to strong if linked to unexpected stability |
| Solubilizer or surfactant system |
Addresses ibuprofen solubility |
Moderate if concentration limits are narrow and performance is demonstrated |
| Low-volume IV formulation |
Improves hospital workflow |
Moderate to strong if concentration and stability are unusual |
| Container or closure combination |
Supports shelf life and compatibility |
Moderate |
| Rapid-release oral tablet |
Supports onset-of-action positioning |
Moderate if dissolution data are distinctive |
| Manufacturing process |
Protects scale-up and quality control |
Stronger when process parameters are difficult to reproduce |
| Lyophilized or reconstitutable dosage form |
Creates a new presentation |
Potentially strong, but development cost is higher |
| Pediatric liquid or dispersible product |
Extends market coverage |
Moderate, with clinical and palatability requirements |
The strongest commercial protection would usually combine formulation, process, and use claims. Trade-secret protection may be more durable for mixing order, temperature controls, impurity limits, and aseptic process parameters that are not necessary to disclose in a patent.
Public patent analysis should separate patents owned by AFT Pharmaceuticals from patents covering third-party excipients or platform technologies. An excipient supplier may license a co-processed excipient, solubilization system, or film-coating technology without owning the drug-product patent.
When does COMBOGESIC lose exclusivity?
COMBOGESIC does not have one global exclusivity date. Exclusivity depends on the country, dosage form, approval pathway, patent scope, and listed patents.
For a conventional small-molecule combination, the principal loss-of-exclusivity events are:
- Expiration of valid formulation or process patents.
- Expiration of method-of-use patents.
- Completion of applicable regulatory exclusivity.
- Approval of a generic or authorized alternative.
- A court decision invalidating or not-infringing a relevant patent.
- Commercial entry under a regulatory pathway that does not require duplication of all product attributes.
In the United States, the Orange Book is the central source for approved drug products, patents, and exclusivity listings. FDA listing does not itself establish that every listed patent will withstand litigation.[3] A generic applicant may file a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or will not be infringed. The product sponsor may then bring patent litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework, subject to statutory conditions.[4]
The applicable commercial risk is greater for an IV formulation because a competing product may need to reproduce sterile, stable, and compatible performance, while an oral competitor may rely on conventional immediate-release technology.
What FDA regulatory issues affect COMBOGESIC excipients?
FDA review focuses on the finished drug product, not merely whether each excipient has prior pharmaceutical use. The agency evaluates the excipient’s route, level, function, impurity profile, and exposure.
For oral products, the main issues are dissolution, uniformity, degradation products, microbial quality where relevant, and labeling. For IV products, the review extends to sterility assurance, bacterial endotoxins, particulate matter, extractables and leachables, container closure integrity, pH, osmolality, and administration compatibility.[5]
A change in excipient grade, supplier, concentration, or manufacturing process can require regulatory assessment even if the excipient itself is well established. The effect depends on the change-control category, product specification, dissolution or stability impact, and local regulatory pathway.
What commercial opportunities exist for COMBOGESIC excipients?
Hospital and perioperative formulations
The IV product offers the largest potential for excipient-enabled differentiation. Hospitals value reduced opioid use, predictable administration, fewer preparation steps, and compatibility with existing infusion systems. A smaller-volume or longer-stability formulation could improve operating-room and emergency-department workflow.
Pediatric products
Pediatric opportunities include oral suspensions, dispersible tablets, granules, and sachets. The main technical constraints are taste, dose flexibility, sedimentation, preservative selection, and age-appropriate dosing. Acetaminophen and ibuprofen already have extensive pediatric use, but the fixed combination requires careful labeling to avoid duplicate dosing with other products.
Geriatric and swallowing-constrained patients
Film-coated smaller tablets, orally disintegrating tablets, and liquid presentations can target patients with dysphagia. These formats require palatability and dose-accuracy data, not merely a new excipient blend.
Private-label and regional licensing
AFT’s product can support regional licensing, hospital tenders, and private-label arrangements where the licensee contributes manufacturing capacity or market access. The most valuable licensing package would include formulation know-how, regulatory files, supply commitments, and territorial rights rather than an excipient alone.
Manufacturing partnerships
Contract development and manufacturing organizations with sterile liquid capabilities are potential partners for IV expansion. Excipient suppliers can participate through qualified grades, technical transfer, stability packages, and joint patent filings covering formulation-process combinations.
How strong is the COMBOGESIC patent estate?
The commercial strength of the estate depends on whether protection covers a reproducible technical solution rather than the basic idea of combining two known analgesics. The likely strength hierarchy is:
- Specific IV composition with demonstrated long-term stability.
- Manufacturing process that controls precipitation, impurities, or particulate matter.
- Container closure and infusion compatibility.
- Rapid-release oral formulation with comparative dissolution data.
- Fixed-dose combination claims without formulation limitations.
- Broad method-of-use claims covering ordinary analgesic treatment.
The estate is stronger where patent claims align with regulatory specifications and manufacturing controls. It is weaker where competitors can change excipients, tablet architecture, concentration, or manufacturing sequence without losing the claimed performance.
What generic entry risks exist?
Generic entry risk differs by presentation.
| Risk factor |
Oral product |
IV product |
| Availability of conventional manufacturing |
High |
Moderate |
| Formulation design-around potential |
High |
Moderate |
| Sterile manufacturing barrier |
Low |
High |
| Need for comparative dissolution work |
High |
Lower than oral, but compatibility and stability are critical |
| Excipient patent exposure |
Moderate |
Potentially high |
| Hospital switching barriers |
Moderate |
Higher where protocols are established |
| Price erosion after entry |
Potentially high |
Moderate to high |
For oral COMBOGESIC, a competitor can often design around a coating, disintegrant, or filler while preserving the same active ingredients and strength. For IV COMBOGESIC, the combination of solubility, stability, sterile processing, and container compatibility raises development costs and may slow entry.
How does COMBOGESIC compare with competing analgesic products?
COMBOGESIC competes with separate acetaminophen and ibuprofen products, IV acetaminophen, injectable NSAIDs, and opioid-based regimens. Its principal commercial advantage is coordinated dosing in a single product. Its principal limitation is that it combines the hepatic safety considerations of acetaminophen with the renal, gastrointestinal, cardiovascular, and bleeding considerations associated with ibuprofen.
The fixed combination is most attractive in protocols that already use both pharmacologic classes. It is less attractive where clinicians require independent titration or where one active ingredient is contraindicated.
Key Takeaways
- COMBOGESIC’s core commercial proposition is a fixed-dose acetaminophen-ibuprofen combination.
- Oral excipient opportunities center on rapid release, tablet size, palatability, and manufacturing efficiency.
- IV excipient opportunities center on solubility, pH, stability, sterility, particulate control, and infusion compatibility.
- The strongest patent strategy links excipient composition to measurable technical effects.
- Hospital IV applications offer the clearest opportunity for premium formulation differentiation.
- Pediatric, dysphagia-friendly, and private-label presentations can extend the commercial platform.
- Generic risk is higher for oral products because conventional excipient substitutions and formulation design-arounds are more accessible.
- Orange Book, FDA exclusivity, Paragraph IV filings, and jurisdiction-specific patent registers determine actual entry timing.[3][4]
FAQs About COMBOGESIC Excipient and Commercial Strategy
Can COMBOGESIC be reformulated with different excipients?
Yes. A competitor may use different fillers, binders, disintegrants, coatings, buffers, or solubilizers if the resulting product meets regulatory, bioequivalence, stability, and performance requirements.
Which excipient technology is most valuable for IV COMBOGESIC?
A technology that maintains acetaminophen and ibuprofen in a stable sterile solution while reducing infusion volume and precipitation risk has the strongest commercial potential.
Can a new COMBOGESIC formulation receive separate patent protection?
Yes. A new formulation may support composition, process, container, stability, or use claims if it is novel, non-obvious, and supported by adequate technical data.
Is an excipient supplier automatically protected from generic competition?
No. The supplier may own rights to an excipient platform, but the drug-product sponsor must establish rights to use the excipient and may need separate protection for the finished formulation.
Does COMBOGESIC require biosimilar analysis?
No. COMBOGESIC contains small-molecule active ingredients, not a biologic. Generic-drug and combination-product pathways are more relevant than biosimilar pathways.
References
-
AFT Pharmaceuticals Limited. (n.d.). COMBOGESIC product information and company materials. AFT Pharmaceuticals.
-
Therapeutic Goods Administration. (n.d.). Australian Register of Therapeutic Goods: COMBOGESIC product records. Australian Government Department of Health and Aged Care.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. §§ 355 and 35 U.S.C. §§ 156, 271, 282.
-
U.S. Food and Drug Administration. (2016). Q8(R2) pharmaceutical development, Q9 quality risk management, and Q10 pharmaceutical quality system. FDA.
